Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Aviance Capital Partners LLC

Aviance Capital Partners LLC trimmed its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 4.3% during the 4th quarter, Holdings Channel reports. The fund owned 79,098 shares of the biopharmaceutical company’s stock after selling 3,555 shares during the quarter. Bristol-Myers Squibb makes up about 0.9% of Aviance Capital Partners LLC’s investment portfolio, making the stock its 29th largest position. Aviance Capital Partners LLC’s holdings in Bristol-Myers Squibb were worth $4,059,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. OFI Invest Asset Management purchased a new position in shares of Bristol-Myers Squibb during the 3rd quarter valued at approximately $25,000. Milestone Investment Advisors LLC acquired a new stake in Bristol-Myers Squibb during the third quarter valued at $27,000. Blue Bell Private Wealth Management LLC increased its holdings in Bristol-Myers Squibb by 61.5% in the third quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 200 shares in the last quarter. Turtle Creek Wealth Advisors LLC acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter worth about $40,000. Finally, Wetzel Investment Advisors Inc. acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at about $40,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently weighed in on BMY. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. Societe Generale cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. BMO Capital Markets cut their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research note on Friday, April 26th. Barclays decreased their price target on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. Finally, StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 15th. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $60.00.

Bristol-Myers Squibb Trading Down 0.2 %

Shares of NYSE BMY traded down $0.09 during trading on Monday, hitting $43.90. 9,110,922 shares of the company were exchanged, compared to its average volume of 15,839,226. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. Bristol-Myers Squibb has a 12-month low of $43.33 and a 12-month high of $69.10. The company has a fifty day moving average price of $50.24 and a 200-day moving average price of $50.57. The firm has a market capitalization of $88.99 billion, a PE ratio of -14.16, a P/E/G ratio of 14.82 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. The company had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. Bristol-Myers Squibb’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.05 earnings per share. As a group, equities research analysts expect that Bristol-Myers Squibb will post 0.59 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th were paid a dividend of $0.60 per share. The ex-dividend date of this dividend was Thursday, April 4th. This represents a $2.40 annualized dividend and a yield of 5.47%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.